• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Antimicrob Agents Chemother. Novel combinations of vancomycin plus ceftaroline or oxacillin against methicillin resistant vancomycin-intermediate Stap

Giuseppe

Emeritus
[Source: Antimicrobial Agents and Chemotherapy, full text: (LINK). Abstract, edited.]

Novel combinations of vancomycin plus ceftaroline or oxacillin against methicillin resistant vancomycin-intermediate Staphylococcus aureus (VISA) and heterogeneous VISA (hVISA).


B.J. Werth 1, C. Vidaillac 1, K.P. Murray 1, K.L. Newton 1, G. Sakoulas 3,4, P. Nonejuie 5, J. Pogliano 5 and M.J. Rybak 1,2

Author Affiliations: <SUP>1</SUP>Anti-Infective Research Laboratory, Eugene Applebaum College of Pharmacy and Health Sciences <SUP>2</SUP>School of Medicine <SUP>3</SUP>Wayne State University, Detroit, MI 48201 <SUP>4</SUP>Department of Pediatric Pharmacology and Drug Discovery, University of California San Diego School of Medicine, La Jolla, CA USA <SUP>5</SUP>University of California San Diego Division of Biology, La Jolla, CA USA



ABSTRACT

We demonstrated a significant inverse correlation between vancomycin and beta-lactam susceptibility in vancomycin-intermediate Staphylococcus aureus (VISA) and heterogeneous VISA (hVISA) isolates. Using time kill assays, vancomycin plus oxacillin or ceftaroline was synergistic against 3/5 VISA and 1/5 hVISA or 5/5 VISA and 4/5 hVISA, respectively. Beta-lactam exposure reduced overall vancomycin-bodipy binding but may have improved vancomycin-cell wall interactions to improve vancomycin activity. Further research is warranted to elucidate the mechanism behind vancomycin and beta-lactam synergy.



FOOTNOTES

Corresponding Author: Michael J. Rybak, Anti-Infective Research Laboratory, Pharmacy Practice ? 4148, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, 259 Mack Ave., Detroit, MI 48201, Tel: (313) 577-4376, Fax: (313) 577-8915, Email: m.rybak@wayne.edu

Copyright ? 2013, American Society for Microbiology. All Rights Reserved.
-
-------
 
Back
Top Bottom